Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.
Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.
复制标题
双嘧达莫单药治疗精神分裂症：通过调节嘌呤能信号传导的新型治疗方法的试点。
DOI：
10.1007/s00213-011-2315-3
复制
发表时间：
2011
影响因子：
3.4
通讯作者：
Thaker,GunvantK
中科院分区：
文献类型：
--
作者：
Wonodi,Ikwunga;Gopinath,HirekaturV;Liu,Judy;Adami,Helene;Hong,LElliot;Allen-Emerson,Robert;McMahon,RobertP;Thaker,GunvantK
研究背景新的数据表明神经调质腺苷可能在精神分裂症的治疗中发挥作用。腺苷A2 A受体刺激对突触后D2 A受体产生功能性拮抗作用。来自精神分裂症相关动物模型的数据支持调节腹侧纹状体中的腺苷能传递的治疗效果。一个先前的临床试验显示，与安慰剂相比，双嘧达莫，腺苷再摄取抑制剂，在改善精神分裂症patients.ObjectivesThe目的阳性症状的优越性，这项研究的目的是检查200毫克/天的双嘧达莫单药治疗对阳性和阴性症状的影响，目的是确定未来精神分裂症后续研究的剂量。一项为期6周的双盲试验，比较奥氮平（20 mg/天）与双嘧达莫单药治疗（200 mg/天）。13名参与者完成了治疗阶段（8双嘧达莫，5奥氮平）。结果奥氮平组表现出优势的BPRS总评分（平均值± SD：总BPRS评分从第1周的36.8 ± 2.3下降到研究结束时的33.2 ± 5.5）的趋势（p= 0.08）。平均总BPRS评分从36.4 ± 5.3下降到34.0 ± 7.7在潘生丁group.ConclusionsAlthough这些试点数据不支持潘生丁单药治疗显着的抗精神病作用，结果提供了一些证据，检查潘生丁（200毫克/天）作为辅助症状性抗精神病药物治疗的精神分裂症患者。
BackgroundEmerging data indicate the neuromodulator adenosine may play a role in the therapeutics of schizophrenia. Adenosine A2Areceptor stimulation exerts a functional antagonism at postsynaptic D2receptors. Data from animal models relevant to schizophrenia support a therapeutic effect of modulating adenosinergic transmission in the ventral striatum. One previous clinical trial showed superiority of adjunctive dipyridamole, an adenosine reuptake inhibitor, compared to placebo in ameliorating positive symptoms in schizophrenia patients.ObjectivesThe aim of this study was to examine the effects of dipyridamole monotherapy of 200 mg/day on positive and negative symptoms, with the goal of determining dosing for future adjunctive studies in schizophrenia.MethodsTwenty symptomatic schizophrenia participants were randomized to a 6-week double-blind trial comparing olanzapine (20 mg/day) to dipyridamole monotherapy (200 mg/day). Thirteen participants completed the treatment phase (eight on dipyridamole; five on olanzapine).ResultsThe olanzapine group showed a trend (p= 0.08) for superiority on BPRS total scores (mean ± SD: total BPRS score decreasing from 36.8 ± 2.3 at week 1, to 33.2 ± 5.5 at the end of the study). The mean total BPRS scores decreased from 36.4 ± 5.3 to 34.0 ± 7.7 in the dipyridamole group.ConclusionsAlthough these pilot data do not support a significant antipsychotic effect of dipyridamole monotherapy, the results provide some evidence for examining dipyridamole (200 mg/day) as adjunct to symptomatic antipsychotic-treated schizophrenia patients.